This round closed on 22 September 2026. The details below are from that round.

KWF

Lead4Life PPP 2026 – Lead-212 Radiopharmaceuticals Program

€0.5M–€2M per project (total program: €5M)||Up to 4 years

12:00 noon; full proposal phase. Matchmaking phase precedes full proposal submission.

Last seen in a scan/import: 3 Jul 2026.

Catalog updated: 4 Jul 2026.

These timestamps are not source verification. Confirm the current deadline and your eligibility on the funder’s call page before applying.

Closed for now. See which open grants match your research. 30s, no email. See my matches →

The KWF Lead4Life PPP 2026 funds public-private partnerships developing lead-212 radiopharmaceuticals, with budgets of €0.5-€2 million per project (total programme: €5M). The call targets Dutch research institutions and commercial partners collaborating on production supply chains or enabling technologies for clinical Pb-212 introduction. This is a one-off, two-stage call with mandatory consortium membership and strict compliance requirements including RVO declarations and patient advisory review.

Details

Funder	KWF
Budget	€0.5M–€2M per project (total program: €5M)
Duration	Up to 4 years
Consortium	Required — public-private partnership consortium; Consortium Agreement between all participants is mandatory
Application	2-stage: matchmaking phase → full proposal (deadline 22 Sep 2026)
Frequency	One-off
Eligible countries	NL

Eligibility & scope

PPP proposals for lead-212 production/supply chain or enabling technologies for clinical introduction of Pb-212 radiopharmaceuticals. Requires active private-party participation (Health~Holland PPP rules), a Consortium Agreement, and compliance with RVO 'no undertaking in difficulty' declaration. Dutch-language summary required for patient advisory review. Netherlands-based institutions; unregistered institutes must register in KWF GMS ≥6 weeks before deadline.

Who Should Apply

•Dutch research institutions (academic medical centres, hospital institutes, university departments) with clinical radiopharmaceutical expertise
•Commercial partners (pharmaceutical, biotech, or radiochemistry manufacturers) committed to supply-chain or technology development
•Consortium leads with experience managing multi-stakeholder agreements and Health~Holland PPP compliance
•Projects focused on lead-212 production capacity, supply logistics, or clinical-translation enablers rather than pure science
•Applicants able to register in KWF GMS system at least 6 weeks before the 22 September 2026 deadline

Key Dates

•Full proposal deadline: 22 September 2026, 12:00 noon (preceded by matchmaking phase)
•Up to four-year project duration
•One-off call; no subsequent rounds planned

Tips for Applicants

✓Form your consortium before entering the matchmaking phase; KWF expects all partners to be aligned on supply-chain or technology scope, not exploratory collaborations.
✓Prepare a Dutch-language patient summary for KWF's patient advisory review, this is mandatory and shaped differently from standard research abstracts.
✓Document RVO 'no undertaking in difficulty' compliance explicitly in your application; KWF audits this and late corrections stall review.

Frequently Asked Questions

What is the budget for the KWF Lead4Life PPP 2026 call?

Up to €2 million per project, with a total programme budget of €5 million. The typical range is €0.5-€2 million depending on project scope.

Who must be in a Lead4Life PPP consortium?

At least one Dutch research institution and one active private-sector partner (manufacturer, biotech, or pharmaceutical company). A formal Consortium Agreement is mandatory for all participants.

What is the matchmaking phase?

An initial stage where potential consortium members are brought together before the full proposal deadline; full proposals are due 22 September 2026.

Do I need to be based in the Netherlands to apply?

Yes, eligible organisations must be Netherlands-based. Unregistered institutes must register in KWF GMS at least 6 weeks before the deadline.

What research focus does Lead4Life PPP support?

Lead-212 radiopharmaceutical production, supply-chain development, or clinical-translation enabling technologies; projects must have clear private-sector participation aligned with commercial viability.

kwfppplead-212radiopharmaceuticaltranslationalnetherlandsconsortium-requiredsupply-chain

Related on Grantsby

KWF writing tips & FAQ
Evaluation criteria, proposal structure, common mistakes.

View full call → KWF writing tips

Share ✉ Email X LinkedIn WhatsApp

Summary generated by AI based on published grant information. Always verify details on the funder's website.

Similar grants

Browse all open grants →

This call has closed. See what's open now.

Get matched against every open call from KWF and the rest of the 65 funders we track, rechecked every week. 30 seconds, no signup needed to preview.

See my matches free →